Q-omics provides the consensus-scored FKBP1B profile across patient tissues and cancer cell-line models. FKBP1B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FKBP1B is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, FKBP1B protein abundance shows 26,964 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where FKBP1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FKBP1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FKBP1B survival associations across molecular data types. FKBP1B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FKBP1B RNA expression–survival associations across cancer types. High FKBP1B expression shows unfavorable associations in ACC, LGG and SKCM, but favorable associations in SCLC, LAML and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FKBP1B RNA expression.
This table summarizes FKBP1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FKBP1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FKBP1B shows lower tumor expression in KIRC, COAD, KIRP, KICH, LUAD and LUSC. The KIRC box plot shows higher FKBP1B RNA expression in normal versus tumor tissue (log2 FC = −1.106, t-test p < 0.001).
This table shows molecular features associated with FKBP1B in patient tissues and cancer cell lines. In patient samples, FKBP1B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FKBP1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
